INTARCIA THERAPEUTICS
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
INTARCIA THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Medical Device Personal Health
Founded:
1997-01-01
Address:
Hayward, California, United States
Country:
United States
Website Url:
http://www.intarcia.com
Total Employee:
251+
Status:
Active
Contact:
617-936-2500
Email Addresses:
[email protected]
Total Funding:
1.68 B USD
Technology used in webpage:
Domain Not Resolving Euro IPv6 Amazon Route 53 Microsoft Apple Whitelist
Similar Organizations
Advanced Animal Diagnostics
Advanced Animal Diagnostics develops diagnostic products to cure on-farm animal diseases.
Aerin Medical
Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Alcresta
Alcresta develops enzyme-based nutritional products for infants and adults with acute and chronic diseases.
American Renal Associates Holdings
American Renal Associates Holdings operates kidney dialysis services and offers outpatient and inpatient dialysis treatments.
Ancora Heart
Ancora Heart is dedicated to helping people with heart failure feel better and live longer.
SpaceOAR
SpaceOAR is a medical device company that develops space-filling hydrogels for radiation oncology and cancer surgery indications.
Binx Health
Binx Health creates new categories of healthcare solutions that deliver on-demand testing to people where they need it most.
Butterfly Network
Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Daktari Diagnostics
Daktari Diagnostics manufactures diagnostic medical products for clinicians and patients.
Elcelyx Therapeutics
Elcelyx Therapeutics is developing nutrient sensing-based products for weight management and obesity-related metabolic disorders.
Enzium
Enzium develops fluorescent based reagents for selective protease.
Galera Therapeutics
Galera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Forward
Forward is a healthcare startup that provides a membership-based health care system.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
ImaginAb
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Impliant
Impliant, Inc. develops novel spine arthroplasty solutions for motion preservation. The company offers TOPS system.
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
iPierian
iPierian is a drug discovery platform that develops therapies for neurodegenerative diseases such as SMA, ALS, and Parkinson’s.
Ivantis
Ivantis is focused on developing an innovative treatment for glaucoma which includes eye drops, laser therapy, and surgery.
jCyte
jCyte is a developer of cell-based technology intended to cure retinitis pigmentosa.
Moximed
Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.
Opus Genetics
Opus Genetics is a gene therapy company for ultra-rare blinding conditions.
Oxford Immunotec
Oxford Immunotec, a medical diagnostics company, develops tests for various diseases based on its innovative T cell measurement technology.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Prima Temp
Prima Temp specializes in fertility detection, early disease detection, and circadian rhythm monitoring.
Amelia Virtual Care
Amelia Virtual Care develops a virtual reality platform designed to bring value to mental health treatment.
CardiacSense
CardiacSense is a developer of a wearable technology for continuous cardiac arrhythmia detection and non-inflating blood pressure monitoring
Syndevrx
SynDevRx develops polymer-based drug conjugates for small molecule drug activity.
UE LifeSciences
UE LifeSciences is a female technology company building preventive oncology solutions for primary care and home.
Unicycive Therapeutics
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs.
Aspira Women's Health
Aspira Women's Health develops and commercializes diagnostic tests that address unmet needs in gynecologic oncology and women’s health.
Know Labs
Know Labs is a non-invasive diagnostic technology platform that uses radio waves to identify and measure molecules in the body.
Vivos Therapeutics
Vivos Therapeutics is a research and development company providing training for health care allowing to integrate breathing wellness.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2015-09-24 | Phoundry Pharmaceuticals | Phoundry Pharmaceuticals acquired by Intarcia Therapeutics | N/A |
Investors List
GGV Capital
GGV Capital investment in Venture Round - Intarcia Therapeutics
SharesPost Investment Management
SharesPost Investment Management investment in Secondary Market - Intarcia Therapeutics
GWC Innovator Fund
GWC Innovator Fund investment in Series E - Intarcia Therapeutics
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series E - Intarcia Therapeutics
The Pritzker Organization
The Pritzker Organization investment in Series E - Intarcia Therapeutics
Foresite Capital
Foresite Capital investment in Series E - Intarcia Therapeutics
The Baupost Group
The Baupost Group investment in Series E - Intarcia Therapeutics
RA Capital Management
RA Capital Management investment in Series E - Intarcia Therapeutics
Baillie Gifford
Baillie Gifford investment in Series E - Intarcia Therapeutics
Kayon Partners
Kayon Partners investment in Series E - Intarcia Therapeutics
Official Site Inspections
http://www.intarcia.com
- Host name: ec2-18-208-125-27.compute-1.amazonaws.com
- IP address: 18.208.125.27
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Intarcia Therapeutics" on Search Engine
Intarcia Therapeutics - Crunchbase Company Profile
Company Type For Profit. Contact Email [email protected]. Phone Number 617-936-2500. Intarcia Therapeutics is a biopharmaceutical company that develops therapies …See details»
Intarcia Therapeutics, Inc. | LinkedIn
Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking...See details»
Intarcia, a former biotech unicorn, gets new life with startup deal
Aug 30, 2023 A private company called i2o Therapeutics, founded in 2019, announced this week it acquired Intarcia’s assets, among them the biotech’s diabetes drug-eluting …See details»
FDA offers former biotech unicorn Intarcia a chance for a panel …
Feb 9, 2023 Dive Brief: The Food and Drug Administration will permit Intarcia Therapeutics to request a public advisory committee hearing for its diabetes drug …See details»
i2o looks to revive diabetes drug-eluting implant from Intarcia
Sep 5, 2023 i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics. The Boston-based company acquired and …See details»
Intarcia Therapeutics Secures Landmark $210 Million Financing …
Nov 15, 2012 Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, …See details»
Intarcia Therapeutics Takes One Last Shot at FDA Approval
Nov 22, 2021 Intarcia Therapeutics Inc., once among the most promising emerging companies in biotech, is taking a rarely used route to dispute not one, but two Food and …See details»
Intarcia Announces Successful Cardiovascular Safety …
May 06, 2016, 10:15 ET. Share this article. BOSTON, May 6, 2016 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced top-line results from its more than 4,000 patient …See details»
Implantable Diabetes Drug-Device Combo From Intarcia Gets …
August 25, 2023. Intarcia Therapeutics will continue its seven-year quest for FDA approval of its drug-device diabetes treatment with an alternative form of hearing — a public …See details»
Intarcia’s device-drug diabetes therapy shut down by FDA panel
Sep 21, 2023 A n advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that …See details»
FDA proposes to refuse Intarcia’s exenatide combo product NDA …
Sep 1, 2021 The US Food and Drug Administration@s (FDA) Center for Drug Evaluation and Research (CDER) has told Intarcia Therapeutics it is proposing to refuse a new …See details»
Intarcia Therapeutics - Funding, Financials, Valuation & Investors
Intarcia Therapeutics is funded by 27 investors. Notable Capital and SharesPost Investment Management are the most recent investors. Intarcia Therapeutics has a …See details»
Intarcia Therapeutics Provides Regulatory Update - FDA Accepts ...
BOSTON, Oct. 8, 2019 /PRNewswire/ -- Intarcia Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission …See details»
FDA once again rejects Intarcia's 6-month diabetes drug implant
By Conor Hale Mar 11, 2020 10:32am. drug delivery FDA rejection implant regulatory. It’s been over two years since its last rejection by the FDA, but now Intarcia Therapeutics …See details»
Intarcia Therapeutics, Inc. | Devex
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery Systemâ„¢ – medicines …See details»
Intarcia Announces Successful Cardiovascular Safety Results in …
May 6, 2016 BOSTON., Intarcia Therapeutics, Inc. today announced top-line results from its more than 4,000 patient Cardiovascular Safety Study (FREEDOM-CVO trial), clearing …See details»
Once valued at more than $5B, Intarcia Therapeutics sees all of …
August 31, 2022 02:49 PM EDT. Pharma. FDA+. Once valued at more than $5B, Intarcia Therapeutics sees all of its execs depart and its final shot at FDA denied. Zachary …See details»
Intarcia, a failed diabetes "unicorn," could be resurrected - Axios
Sep 20, 2023 - Economy. Intarcia, a failed diabetes "unicorn," could be resurrected. Dan Primack. , author of. Axios Pro Rata. Illustration: Annelise Capossela/Axios. It's been …See details»
Intarcia Therapeutics Secures Landmark $210 Million Financing …
Nov 15, 2012 Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, …See details»
Intarcia Therapeutics acquired by i2o Therapeutics - Crunchbase
Aug 30, 2023 Acquiring Organization: i2o Therapeutics I2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies. Announced …See details»